Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16258061 | 0.94 | CYP2C9 (0.35) | FASNCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL2398862 | 0.93 | FASN (0.34) | FASNMAPT | |
| SCHEMBL2393972 | 0.93 | FASN (0.36) | FASNCYP2C9CYP3A4APP | |
| SCHEMBL12625795 | 0.92 | CYP2C9 (0.34) | FASNCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL15744862 | 0.92 | CYP2C9 (0.34) | FASNCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL15744603 | 0.92 | CYP2C9 (0.34) | FASNCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL12625975 | 0.91 | FASN (0.35) | FASNCYP2C9CYP3A4APP | |
| SCHEMBL12625007 | 0.91 | CYP2C9 (0.34) | FASNCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL12626255 | 0.91 | FASN (0.33) | FASN | |
| SCHEMBL13002531 | 0.90 | CYP2C9 (0.41) | FASNCYP2C9ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211513-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-03 | — | — | US | disclosed |
| US-8211513-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-03 | — | — | US | disclosed |
| US-8211513-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-03 | — | — | US | disclosed |
| US-20110233466-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110233466-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110233466-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2368966-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368966-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-7846514-B2 | Liquid crystal compound, liquid crystal composition and, liquid crystal display device | CHISSO CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20100073621-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT | CHISSO CORPORATION (JP) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100073621-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT | TRPV4, TRPV5, ZKSCAN2 | FASN 1925/4885CYP2C9 2077/4885ALDH1A1 4257/4885 |
| US-20110233466-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | CFB, CFD, LCT | FASN 2699/4885CYP2C9 1926/4885ALDH1A1 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.